

Abstract Reports from the American Association for the Study of Liver Disease



[Print this page](#)

1. GRAFT AND PATIENT SURVIVAL IN PATIENTS WITH HCV UNDERGOING LIVING DONOR LIVER TRANSPLANTATION COMPARED TO CADAVERIC LIVER TRANSPLANTATION- Abstract 51

Eric D Goldberg, Fredric D Gordon, Elizabeth A Pomfret, James J Pomposelli, Stephen C Fabry, W David Lewis, Roger L Jenkins, Lahey Clinic Medical Center, Burlington, MA

2. LONG TERM QUALITY OF LIFE FOLLOWING LIVER TRANSPLANTATION IN RECIPIENTS WITH HEPATITIS C VIRUS (HCV): RESULTS FROM THE NIDDK LIVER TRANSPLANTATION DATABASE (LTD)--Abstract 52

Steven H Belle, Kris Ruppert, University of Pittsburgh, Pittsburgh, PA; Nathan M Bass, University of California San Francisco, San Francisco, CA; Katherine Detre, Yuling Wei, University of Pittsburgh, Pittsburgh, PA; James E Everhart, National Institutes of Health, Bethesda, MD; Daniel Schafer, University of Nebraska Medical Center, Omaha, NE; Russell Wiesner, Mayo Clinic, Rochester, MN

3. THE IMPACT OF PRE-TRANSPLANT METHADONE AND NARCOTIC USE ON TRANSPLANT CANDIDACY AND OUTCOMES—Abstract 84

Fredric D Gordon, Eric Richman, Alyson Nixon, JoAnne Pratt, Patricia A Conway, Eric D Goldberg, James J Pomposelli, Elizabeth A Pomfret, David Lewis, Lahey Clinic Medical Center, Burlington, MA

4. INCREASED MORBIDITY AND MORTALITY WITH HCV/HIV COINFECTION RELATIVE TO HCV OR HIV MONOINFECTION AMONG U.S. VETERANS—Abstract # 409

Fredric D Gordon, Eric Richman, Alyson Nixon, JoAnne Pratt, Patricia A Conway, Eric D Goldberg, James J Pomposelli, Elizabeth A Pomfret, David Lewis, Lahey Clinic Medical Center, Burlington, MA

5. HEPATITIS C VIRUS INFECTION AND INCIDENT TYPE 2 DIABETES MELLITUS—Abstract 433

Shruti H Mehta, Fred L Brancati, Steffanie A Strathdee, Johns Hopkins University, Baltimore, MD; James Pankow, University of Minnesota, Minneapolis, MN; Dale Netski, Joseph Coresh, Moyses Szklo, David L Thomas, Johns Hopkins University, Baltimore, MD

6. STEATOSIS DOES NOT INFLUENCE SUSTAINED VIROLOGIC RESPONSE RATES IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.—Abstract 471

Heather M Patton, Scripps Clinic, La Jolla, CA; Cynthia Behling, University of California Medical Center, San Diego, CA; Keyur Patel, Paul J Pockros, Shanon Heaton, Lawrence M Blatt, John G McHutchison, Scripps One, La Jolla, CA

7. PREVALENCE OF DEPRESSION AND SUICIDAL IDEATION IN HEPATITIS C PATIENTS TREATED WITH COMBINATION INTERFERON AND RIBAVIRIN THERAPY: EFFECT ON ADHERENCE TO THERAPY—Abstract # 517

David E Bernstein, Danielle Belkin, Stephen Steinberg, North Shore University Hospital, Manhasset, NY

8. RESPONSE OF AFRO-AMERICAN PATIENTS WITH CHRONIC HEPATITIS C TO CURRENT VIRICIDAL THERAPY—abstract 479

Carroll B Leevy, Salim Al-Khatat neh, Serban A Moroianu, UMDNJ-Liver Center, Newark, NJ

9. SPONTANEOUS VIRAL CLEARANCE IN PATIENTS WITH ACUTE HEPATITIS C: PREDICTABILITY BY REPEATED MEASUREMENTS OF SERUM HCV CONCENTRATION—Abstract 492

Harald Hofer, Internal Medicine IV, Dept. of Gastroenterology and Hepatology, Vienna, Austria; Thomas Watkins.Riedel, Dept of Clinical Virology, Vienna, Austria; Oskar Janata, SMZ-Ost, Vienna Austria; Edward Penner, Alfred Gangi, Peter Ferenci, Internal Medicine VI, Dept. of Gastroenterology and Hepatology, Vienna, Austria

10. LOWER LEVELS OF ADHERENCE TO THERAPY INFLUENCE SUSTAINED RESPONSE RATES IN

CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA 2B PLUS R1BAVIRIN—abstract 497

John G McHutchison, Keyur Patel, Scripps Clinic, La Jolla, CA; Michael P Manns, Medical School of Hannover, La Jolla, CA; Thierry Poynard, Hepato Gastro Groupe Hospitalier, Paris, France; Jules L Dienstag, Massachusetts General Hospital, Boston, MA; Janice K. Albrecht, Schering Plough Research Institute, Kenilworth, NJ

11. SEVERE DEPRESSION INDUCED BY HCV RESULTS IN DECREASED COMPLIANCE TO TREATMENT AND VIRAL RESPONSE—Abstract 513

Nydia Sanchez, Louis Lambiase, Jianjun Li, Division of GI and Hepatology, University of Florida Jacksonville, Jacksonville, FL

12. ACCELERATED HEPATIC FIBROSIS PROGRESSION IN HIV AND HCV: CO-INFECTED PATIENTS MAY BE PREDICTED BY ALT - Abstract 746

Abdul HMohsen, Chris Taylor, King's College Hospital, London, UK; Ranjababu Ku lasegaram, St Thomas' Hospital, London, UK; Bernard Portmann, Phillips Easterbrook, Suzanne Norris, King's College Hospital, London, UK

13. RATE OF PROGRESSION TO CIRRHOSIS AND RELATED RISK FACTORS IN 754 INTRAVENOUS DRUG USERS (IVDUS) WITH CHRONIC HCV INFECTION - Abstract 750

Eliseo Minola, Franco Maggiolo, Department of Infectious Disease-Ospedali Riuniti di Bergamo, Bergamo, Italy; Mirella Fraquelli, Alice Colucci, Postgraduate School of Gastroenterology, IRCCS Ospedale Maggiore, Milan, Italy; Daniele Prati, Blood Transfusion and Transplantation Immunology Center, IRCCS Ospedale Maggiore, Milan, Italy; Diego Ripamonti, Osvaldo Fracassetti, Gianpaolo Quinzan, Fredy Suter, Department of Infectious Disease-Ospedali Riuniti di Bergamo, Bergamo, Italy; Dario Conte, Postgraduate School of Gastroenterology, IRCCS Ospedale Maggiore, Milan, Italy

14. HEPATITIS C VIRUS AND SEROLOGICALLY SILENT HEPATITIS B VIRUS COINFECTION IN FORMER OPIATE ADICTS IN METHADONE-MAINTENANCE TREATMENT (MMT) - Abstract 764

Gavin Bart, Paola Piccolo, The Rockefeller University, New York, NY; Aaron Wells, New York Presbyterian Hospital-Cornell Medical Center, New York, NY; Ann Ho, The Rockefeller University, New York, NY; Linqi Zhang, Aaron Diamond Research Center, New York, NY; Sara Handy, The Rockefeller University, New York, NY; Robert Schaefer, Ira Jacobson, New York Presbyterian Hospital-Cornell Medical Center, New York, NY; Mary Jeanne Kreek, The Rockefeller University, New York, NY

15. PROSPECTIVE STUDY OF DEPRESSION IN TREATED AND UNTREATED PATIENTS WITH CHRONIC HEPATITIS C - Abstract 777

Céline Goldberger, Hopital Sainte Anne, Paris, France; Nathalie Boyer, Corinne Castelnau, Michèle Pouteau, Nathalie Giully, Marie-Pierre Ripault, Service d'hépatologie, Hopital Beaujon, Clichy, France; Jean Adés, Service de Psychiatrie, Hopital Louis Mourier, Colombes, France; Patrick Marcellin, Service d'hépatologie, Hopital Beaujon, Clichy, France

16. STEATOSIS DECREASES SIGNIFICANTLY FOLLOWING SUCCESSFUL ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS C INFECTION—abstract 470

Heather M Patton, Scripps Clinic, La Jolla, CA; Cynthia Behling, University of California Medical Center, San Diego, CA; Keyor Patel, Paul Pockros, Shannon Heaton, Lawrence M Blatt, John G McHutchison, Scripps Clinic, La Jolla, CA

17. CONCOMITANT ddI/d4T AND INTERFERON (STANDARD OR PEGYLATED IFN)/RIBAVIRIN TREATMENTS MAY INDUCE A HIGH RISK OF MITOCHONDRIAL TOXICITY IN HIV/HCV CO-INFECTED PATIENTS (ANRS HCO2- RIBAVIC STUDY)—abstract 481

Ravy Hor, Juliette Deshayes, Firouze Bani sadr, Stanislas Pol, Service d'hépatologie, Necker, Paris, France; Eric Rosenthal, Service de médecine interne, Nice, France; Christian Perronne, 1-hopital R. Poincaré, Service des maladies infectieuses, Garches, France; Fabrice Carrat, UL444, Hôpital Saint Antoine, Paris, France

18. RACIAL/ETHNIC DIFFERENCES IN HEMATOLOGIC TOXICITY OF PEGYLATED INTERFERON AND RIBAVIRIN THERAPY: ANALYSIS OF THE WIN-R TRIAL—Abstract 518

Robert Brown, Columbia University College of Physicians and Surgeons, New York, NY; Ira Jacobson, Weill Medical College of Cornell University, New York, NY; Nezam Afdhal, Beth Israel, Boston, MA; Ray Rubin, Piedmont Hosp, Atlanta, GA; James Spivey, Mayo Jacksonville, Jacksonville, FL; Frederic Regenstein, Tulane, New Orleans, LA; David Bernstein, North Shore Univ Hosp, Manhasset, NY; Clifford Brass, Schering Plough Corporation, Kenilworth, NJ; Bradley Freilich, WIN-R Study Group, St Josephs Hosp, Kansas City, MO

19. Peginterferon Alfa-2a (40KD) (PEGASYS®) in Combination with Ribavirin in African American and Caucasian Patients with HCV Genotype 1: A Preliminary Report of a Comparative, Multicenter, Efficacy and Safety Study – Abstract 784

Lennox J. Jeffers, Miami VA Medical Center, Miami, Fla; William Cassidy, Louisiana State University Health Sciences Center, Baton Rouge, La; Charles Howell, University of Maryland School of Medicine, Baltimore, Md; Christopher O'Brien, University of Miami School of Medicine, Miami, Fla; Michael Dragutsky, Gastroenterology Center of the MidSouth, PC, Memphis, Tenn; Michael Fallon, University of Alabama, Birmingham, Ala; Samuel Daniel, North General Hospital, New York, NY; Michael Dolker, Rajinder K. Sidhu, George E. Harb, Roche Laboratories Inc, Nutley, NJ.

20. EARLY HCV GENOTYPE 4 REPLICATION KINETICS DURING TREATMENT WITH PEGINTERFERON ALFA-2A (PEGASYS)-RIBAVIRIN COMBINATION. A COMPARISON WITH HCV GENOTYPES 1 AND 3 KINETICS—abstract 511

Jean-Michel Pawlotsky, Christophe Hezode, Bertrand Peilegrin, Alexandre Soulier, Hopital Henri Mondor, Universite Paris XII, Creteil, France; Michael von Wagner, University of Frankfurt, Frankfurt, Germany; Johannes T Brouwer, University of Rotterdam, Rotterdam, Netherlands; Gabriele Missale, University of Parma, Parma, Italy; Georgios Germanidis, Papageorgiou General Hospital, Thessaloniki, Greece; Yoav Lurie, Kaplan Medical Center, Tel Aviv, Israel; Francesco Negro, Centre Hospitalier Universitaire Cantonnai, Geneva, Switzerland; Juan Estehan, Hospital Vail d'Hebron, Barce lona, Spain; Kriseoffer Helistrand, University of Goteborg, Goteborg, Sweden; Carlo Ferrari, University of Parma, Parma, Italy; Stefan Zeuzem, University of Frankfurt, Frankfurt, Germany; Soiko W Schaim, University of Rotterdam, Rotterdam, Netherlands; Avidan Neumann, Bar-Ilan University, Ramat-Gan, Israel; DITTO Group, European Commission, Brussels, Belgium

21. FACTORS PARTICIPATING IN SEVERE HCV-RELATED LIVER DISEASE IN HIV/HCV CO-INFECTION—abstract 741

Emmanuel Lupoile, Giovanna Vona, Daniel Canioni, Marie Laure Chaix, Bertrand Nalpas, Helene Fontaine, Christian Brechot, Stanislas Pol, Service d'hepatologie, INSERM U-370, Necker, Paris, France

22. HEPATIC STEATOSIS IS ASSOCIATED WITH DISEASE PROGRESSION OF CHRONIC HEPATITIS C: A LARGE COHORT STUDY IN THE UNITED STATES –abstract 745

Ke-Qin Hu, Loma Linda University and VA Medical Center, Loma Linda, CA; Eric Esrailian, USC School of Medicine, Los Angeles, CA; Kevin Thompson, Loma Linda University Medical Center, Loma Linda, CA; Resa Chase, Loma Linda University and VA Medical Center, Loma Linda, CA; Namgyal Kyulo, Mateen Hassen, Fouad Abdeihalim, Donald J Hillebrand, Loma Linda University Medical Center, Loma Linda, CA; Bruce A Runyon, Pancho Los Amigos Medical Center, Downey, CA

23. HEPATITIS C VIRUS INFECTION AS A RISK FACTOR FOR DEVELOPMENT OF TYPE 2 DIABETES MELLITUS: A PROSPECTIVE CROSS-SECTIONAL STUDY—abstract 756

Claudia U Zein, Ananda Basu, Mohamed A Metwally, Nizar N Zein, Mayo Clinic, Rochester, MN

24. COMPLEXITY AND DIVERSITY OF HCV RNA IN AFRICAN AMERICANS –Abstract 161

Erica D Keenan, Susan D Rouster, University of Cincinnati, Cincinnati, OH; Kenneth E Sherman, Univ. of Cincinnati College of Medicine, Cincinnati, OH

25. TWICE WEEKLY ADMINISTRATION OF PEGINTRON IMPROVES VIRAL KINETICS IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1—abstract 502

Elisabeth Formann, Wolfgang Jessner, University of Vienna, Vienna, Austria; Martin Hartmann, MDS Pharma Services, Wangen, Switzerland; Peter Ferenci, University of Vienna, Vienna, Austria

26. INTRAHEPATIC AND SERUM HCV RNA LOADS BEFORE AND AFTER ANTI-HCV TREATMENT IN HIV-HCV CO-INFECTED PATIENTS – Abstract 767

Pascale Trimoulet, Laboratoire de Virologie, Bordeaux, France; Didier Neau, Fédération des Maladies Infectieuses, Bordeaux, France; Anne Rullier, Brigitte Le Bail, Laboratoire d'Anatomie Pathologique, Bordeaux, France; Anne-Christine Jouvencel, Laboratoire de Virologie, Bordeaux, France; Ingrid Laurandeau, Michel Vidaud, Laboratoire de Génétique Moléculaire, Paris, France; Paulette Bioulac-Sage, Laboratoire d'Anatomie Pathologique, Bordeaux, France; Hervé Fleury, Marie-Edith Lafon, Laboratoire de Virologie, Bordeaux, France

27. 24 WEEKS OF TREATMENT WITH PEG-INTERFERON ALFA-2B PLUS RIBAVIRIN IN PATIENTS INFECTED WITH HCV GENOTYPE 2 AND 3 – Abstract 787

Johannes Wiegand, Medical School Hannover, Hannover, Germany

28. THERAPY WITH PEGYLATED INTERFERON PLUS RIBAVIRIN IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C – Abstract 801

Miriam Romero, Marina Nunez, Mayte Perez-Olmeda, Juan Gonzalez, Angeles Castro, Jose Ramon Arribas, Pablo Barreiro, Vicente Soriano, Javier Garcia-Samaniego, Hospital Carlos III, Madrid, Spain

29. Clinical Implications of Testing Viral Response During Ribavirin and Peginterferon Alfa-2b Treatment for Chronic Hepatitis C—abstract 472

John B Wong, Tufts-New England Medical Center, Boston, MA; Gary L Davis, Baylor University Medical Center, Dallas, TX; John G McHutchison, Scripps Clinic, La Jolla, CA; Michael P Manns, Medizinische Hochschule Hannover, Hannover, Germany; Janice K Albrecht, Schering Plough Research Institute, Kenilworth, NJ.

30. Effect of Treatment Management Algorithms on Ribavirin and Peginterferon Alfa-2b Costs for Chronic Hepatitis C – abstract 524

John B Wong, Tufts-New England Medical Center, Boston, MA; Gary L Davis, Baylor University Medical Center, Dallas, TX; John G McHutchison, Scripps Clinic, La Jolla, CA; Michael P Manns, Medizinische Hochschule Hannover, Hannover, Germany; Janice K Albrecht, Schering-Plough Research Institute, Kenilworth, NJ

31. The Discovery of BILN 2061 – An Orally Bioavailable Small Molecule Inhibitor of the HCV Serine Protease and a Promising Antiviral for Treatment of Hepatitis C—abstract 464

Daniel Lamarre, Murray Bailey, Gordon Bolger, Dale Cameron, Mireille Cartier, Anne-Marie Faucher, Nathalie Goudreau, George Kukolj, Lisette Lagace, Arnim Pause, Jean Rancourt, Diane Thibeault, Youla Tsantrizos, Montse Lii nas-Brunet, Boehringer Ingelheim (Canada) Ltd, Research and Development, Laval, PQ, Canada

32. Safety, Tolerability and Antiviral Effect of BILN 206, A Novel HCV Serine Protease Inhibitor, After Oral Treatment Over 2 Days in Patients with Chronic Hepatitis C, Genotype 1, with Advanced Liver Fibrosis—abstract 563

Yves Benhamou, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Holger Hinrichsen, I Medizinische Universitätsklinik, Kiel, Germany; Roel Sentjens, Academic Medical Center, Amsterdam, Netherlands; Markus Reiser, Medizinische Universitätsklinik, Bochum, Germany; Michael P Manns, Medizinische Hochschule, Hannover, Germany; Xavier Forns, Hospital Clinico, Barcelona, Spain; Christina Avendano, Clinica Puerta de Hierro, Madrid, Spain; Jens Crönlein, Gerhard Nehmiz, Gerhard Steinmann, Boehringer Ingelheim Pharma KG, Biberach, Germany

33. Tolerability and Pharmacokinetics of BILN 2061, A Novel HCV Serine Protease Inhibitor, After Oral Single Doses of 5 to 2400 mg in Healthy Male Subjects – abstract 800

Hans Narjes, Boehringer Ingelheim Pharma KG, Biberach, Germany; Chan Loi Yong, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT; Hildegard Stähle, Gerhard Steinmann, Boehringer Ingelheim Pharma KG, Biberach, Germany

34. First Report on the Antiviral Efficacy of BILN 2061, A Novel Oral HCV Serine Protease Inhibitor, in Patients with Chronic Hepatitis C, Genotype 1 – abstract 866

Holger Hinrichsen, I Medizinische Universitätsklinik, Kiel, Germany; Yves Benhamou, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Markus Reiser, Medizinische Universitätsklinik, Bochum, Germany; Roel Sentjens, Academic Medical Center, Amsterdam, Netherlands; Hemer Wedemeyer, Medizinische Hochschule, Hannover, Germany; Jose L Calleja, Clinica Puerta de Hierro, Madrid, Spain; Xavier Forns, Hospital Clinico, Barcelona, Spain; Jens Crönlein, Gerhard Nehmiz, Gerhard Steinmann, Boehringer Ingelheim Pharma KG, Biberach, Germany

35. Treatment of Chronic Hepatitis C with ISIS 14803, An Antisense Oligonucleotide Inhibitor of HCV. Effect of Target Region Sequence of Antiviral Efficacy—abstract 469

Muriel Soler, Hopital Henri Mondor, Université Paris XII, Créteil, France; John G McHutchison, Scripps Clinic, La Jolla, CA; Jesse Kwok, Andrew Dorr, Isis Pharmaceuticals, Carlsbad, CA; Jean-Michel Pawlotsky, Hopital Henri Mondor, Université Paris XII, Créteil, France

36. A Phase IB Dose Escalation Trial of ISIS 14803, an Antisense Inhibitor of HCV, in Patients with Chronic HCV: Final Report – abstract 562

J G McHutchison Sr., P J Pockros, K Patel, L Nyberg, Scripps Clinic, La Jolla, CA; R Z Yu, T J Kwok, F A Dorr, Isis Pharmaceuticals, Inc., Carlsbad, CA

37. A Phase II, 12-Week Study of ISIS 14803, an Antisense Inhibitor of HCV for the Treatment of Chronic Hepatitis C – abstract 795

S C Gordon, William Beaumont Hospital, Royal Oak, MI; B R Bacon, Saint Louis University, St. Louis, MO; I M Jacobson, Weill Medical College of Cornell University, New York, NY; M L Shiffman, Medical College of Virginia, Richmond, VA; N H Afdhal, Beth Israel Deaconess Medical Center, Boston, MA; J G McHutchison, Scripps Clinic, La Jolla, CA; T J Kwok, F A Dorr, Isis Pharmaceuticals, Inc., Carlsbad, CA

38. A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Escalating Doses

of a Novel Recombinant Human Albumin-Interferon a Fusion Protein (Albuferon™) in Subjects with Chronic Hepatitis C – abstract 490

Gary L Davis, University of Florida, Gainesville, FL; Vijayan Balan, Mayo Clinic, Phoenix, AZ; Mark S Sulkowski, John Hopkins, Baltimore, MD; Jianjun Li, University of Florida, Jacksonville, FL; Robert Redfield, University of Maryland, Baltimore, MD; Blaire Osborn, James Murray, Maria Walker, William Freimuth, Human Genome Sciences, Inc., Rockville, MD

39. A Phase II Randomized, Double Blind, Placebo Controlled Study of Tumor Necrosis Factor Antagonist (Etanercept, Enbrel®) as an Adjuvant to Interferon and Ribavirin in Naïve Patients with Chronic Hepatitis C – abstract 566

Nizar N Zein, ETANERCEPT Study Group, Mayo Clinic, Rochester, MN

40. Analysis of Hepatic Decompensations and Their Impact on the Natural History of Hepatitis C Virus-Related Cirrhosis—abstract 749

M Rivera, Hospital del Mar, Barcelona, Spain; M A Alvarez, S Montoliu, Hospital Germans Trias i Pujol, Badalona, Spain; B Ballesté, Hospital del Mar, Barcelona, Spain; V Lorenzo-Zuniga, Hospital Germans Trias i Pujol, Badalona, Spain; C Vila, Hospital del Mar, Barcelona, Spain; R M Morillas, Hospital Germans Trias i Pujol, Badalona, Spain; S Coll, Hospital del Mar, Barcelona, Spain; R Durandez, Hospital Germans Trias i Pujol, Badalona, Spain; Ricard Sola, Hospital del Mar, Barcelona, Spain; Ramon Planas Sr., Hospital Germans Trias i Pujol, Badalona, Spain

41. Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) Combination Therapies in Patients Who Relapsed on Rebetron Therapy—abstract 781

Steven K Herrine, Thomas Jefferson University, Philadelphia, PA; Robert Brown Jr, Columbia Presbyterian Medical Center, New York, NY; Stephen Esposito, 1-hepatobiliary Associates of New York, Bayside, NY; David F Bernstein, North Shore University Hospital, Manhasset, NY; Helen Te, University of Chicago, Chicago, IL; Joseph S Galati, Gastroenterology and Liver Associates, Houston, TX; Anna S Lok, University of Michigan, Ann Arbor, MI; Michael S Ondovik, Ellen Lentz, George F Harb, Roche Laboratories Inc., Nutley, NJ

42. PEGINTERFERON ALFA-2A (40KD) (PEGASYS®) PLUS RIBAVIRIN IN CHRONIC HEPATITIS C: RETREATMENT OF PATIENTS WHO RE LAPSED VIROLOGICALLY AFTER 24 WEEKS OF THERAPY—abstract 794

Fernando Goncales, Hospital Das Clinicas, UNICAMP, Campinas, Brazil; David E Bern stein, North Shore University Hospital, Manhasset, NY; Carl Berg, University of Virginia Health Science Center, Charlottesville, VA; Hoel Sette Jr, Instituto de Infectologia “Emilio Ribas”, Sao Paulo, Brazil; Jens Rasenack, Universita tslinik Freiburg, Freiburg, Germany; Moises Diago, Hospital General de Va lencia, Valencia, Spain; Donald M Jensen, Rush-Presbyterian-St. Luke’s Hospital, Chicago, IL; W Graham F Cooksley, Royal Brisbane Hospital, Bris bane, Australia; Philippa Roberts, Andrew M Ackrill, Roche Products Ltd., Welwyn Garden City, UK

43. Epoetin Alfa (Procrit®) Once Weekly Maintains Ribavirin Dose in Hepatitis C Virus (HCV)-Infected Patients Treated with Combination Therapy: Interim Results of a Randomized, Double-blind, Placebo-Controlled Study—abstract 493

Douglas T Dieterich, Mt. Sinai School of Medicine, New York, NY; Paul J Pockros, Scripps Clinic, La Jolla, CA; Eugene R Schiff University of Miami School of Medicine, Miami, FL; Mitchell L Shiffman, Medical College of Virginia, Richmond, VA; Mark S Sulkowski, Johns Hopkins School of Medicine, Baltimore, MD; Teresa Wright, San Francisco VA Hospital, San Francisco, CA; Peter J Bowers, Ortho Biotech Products, LP for the PROACTIVE IStudy Group, Raritan, NJ

44. Pathological Evolution of HCV-Healthy Carriers: A Multivariate Analysis—abstract 751

Rodolphe Sobesky, Pascal Lebray, Bertrand Nalpas, Anaïs Vallet-Pichard, Helène Fontaine, Jean-Luc Lagneau, Stanislas Pol. From the Service d’Hépatologie and INSERM U370, Hôpital Necker, 149 rue de Sèvres, 75015 Paris, France.

45. Minimal Hepatic Fibrosis in Long-Term Active Injection Drug Users—abstract 747

Lorna M Dove, Columbia University, New York, NY; Karen Seal, Alex McNees, University of California-San Francisco, San Francisco, CA; Brian Herndier, University of California-San Diego, San Diego, CA; Teresa L Wright, Brian Edlin, University of California-San Francisco, San Francisco, CA

46. Hepatitis C Virus Dynamics During Therapy with Peginterferon Alfa-2a(PEGASYS®) Compared to Peginterferon Alfa-2b (PEGINTRON®) in Naïve Patients with Chronic Hepatitis C—abstract 159

Raffaele Bruno, IRCCS S. Matteo Hospital Pavia-University of Pavia, Pavia, Italy; Maurizia Debiaggi, University of Pavia, Pavia, Italy; Valentina Ciappina, Elena Maffezzini, Savino Patrino, Paolo Sacchi, Gaetano Filice, IRCCS S. Matteo Hospital Pavia-University of Pavia, Pavia, Italy

47. Efficacy and Safety of Combined Interferon and Ribavirin Therapy in Cirrhotic Patients Infected with Hepatitis C Virus (HCV) Awaiting Liver Transplantation—abstract 44

Montserrat Garcia-Retortillo, Xavier Forns, Hospital Clinic, Barcelona, Spain; Francisco Snarez, Hospital Juan Canalejo, La Coma, Spain; Trinidad Serrano, Hospital Clinico, Zaragoza, Spain; Manuel D La Mata, Hospital Reina Sofia, Cordoba, Spain; Miquel Navasa, Antoni Rimola, Juan Carlos Garcia-Valdecasas, Juan Rodes, Hospital Clinic, Barcelona, Spain